Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory partial seizures
2008-002455-25Phase 3Completed
- Sponsor
- BIAL
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of eslicarbazepine acetate in epilepsy and Focal aware non-motor seizure (FAS) (3 arms), sponsored by BIAL. Primary endpoint: Primary: Change in seizure frequency (per 4 weeks) during 12-week maintenance vs 8-week baseline. Started Jun 2008; status: completed.
02
Drugs
eslicarbazepine acetate
03
Conditions
epilepsyFocal aware non-motor seizure (FAS)
Beyond the preview
Go deeper on 2008-002455-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002455-25.